Your browser doesn't support javascript.
loading
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
Bristow, Robert G; Alexander, Brian; Baumann, Michael; Bratman, Scott V; Brown, J Martin; Camphausen, Kevin; Choyke, Peter; Citrin, Deborah; Contessa, Joseph N; Dicker, Adam; Kirsch, David G; Krause, Mechthild; Le, Quynh-Thu; Milosevic, Michael; Morris, Zachary S; Sarkaria, Jann N; Sondel, Paul M; Tran, Phuoc T; Wilson, George D; Willers, Henning; Wong, Rebecca K S; Harari, Paul M.
Afiliação
  • Bristow RG; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: robert.bristow@manchester.ac.uk.
  • Alexander B; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Baumann M; OncoRay, Dresden, Germany.
  • Bratman SV; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Brown JM; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Camphausen K; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Choyke P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Citrin D; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Contessa JN; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA.
  • Dicker A; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Kirsch DG; Department of Radiation Oncology and Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA.
  • Krause M; OncoRay, Dresden, Germany.
  • Le QT; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Milosevic M; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Morris ZS; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Sarkaria JN; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Sondel PM; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Tran PT; Department of Radiation Oncology and Molecular Radiation Sciences, Department of Oncology, and Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wilson GD; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA.
  • Willers H; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wong RKS; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Harari PM; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
Lancet Oncol ; 19(5): e240-e251, 2018 05.
Article em En | MEDLINE | ID: mdl-29726389
ABSTRACT
The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioterapia (Especialidade) / Medicina de Precisão / Terapia de Alvo Molecular / Quimiorradioterapia / Fatores Imunológicos / Imunoterapia / Neoplasias / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Lancet Oncol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioterapia (Especialidade) / Medicina de Precisão / Terapia de Alvo Molecular / Quimiorradioterapia / Fatores Imunológicos / Imunoterapia / Neoplasias / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Lancet Oncol Ano de publicação: 2018 Tipo de documento: Article